Literature DB >> 20213458

Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study.

Daniel D Buchanan1, Kevin Sweet, Musa Drini, Mark A Jenkins, Aung Ko Win, Michael Gattas, Michael D Walsh, Mark Clendenning, Diane McKeone, Rhiannon Walters, Aedan Roberts, Alasdair Young, Heather Hampel, John L Hopper, Jack Goldblatt, Jill George, Graeme K Suthers, Kerry Phillips, Graeme P Young, Elizabeth Chow, Susan Parry, Sonja Woodall, Kathy Tucker, Amanda Muir, Michael Field, Sian Greening, Steven Gallinger, Jane Green, Michael O Woods, Renee Spaetgens, Albert de la Chapelle, Finlay Macrae, Neal I Walker, Jeremy R Jass, Joanne P Young.   

Abstract

OBJECTIVE: Hyperplastic polyposis is a colonic polyposis condition of unknown aetiology. The purpose of this study was to examine the spectrum of phenotypic variation in patients with multiple serrated polyps as a basis for gene discovery.
METHODS: One hundred and twenty-six patients with multiple (> or = 5) serrated polyps were recruited to the study. Polyp counts were extracted from histology and colonoscopy reports. Ethnicity was self-reported. Family history of cancer data were derived from pedigrees. Ascertainment status was classified as either index case or identified by screening.
RESULTS: The average reported polyp count was 39. Patients with highest polyp numbers were more likely to be male (P = 0.02). Colorectal cancer (CRC) was identified in 49 of 119 patients (41%) and 28% of these patients had multiple CRC. Young onset patients had higher polyp numbers (P = 0.03) and were more likely to have their CRC in the distal colon (P = 0.02). CRC was significantly associated with the presence of adenomas (P = 0.03). Patients were divided into moderate polyposis (5-79 serrated polyps) and dense polyposis (80 or more) categories. The dense polyposis category was associated with a lack of family history for CRC (P = 0.034) and male gender (P = 0.014), independent of ascertainment status and recruitment site.
CONCLUSION: Multiple serrated polyps were associated with an increased personal risk of CRC. A subset of patients with the highest polyp numbers was more likely to be male and to have no family history of CRC. This result suggests heterogeneous modes of inheritance and has implications for studies investigating the genetic basis of multiple serrated polyps.

Entities:  

Mesh:

Year:  2010        PMID: 20213458      PMCID: PMC2862176          DOI: 10.1007/s00384-010-0907-8

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


Introduction

The recognition of the serrated neoplasia pathway has facilitated investigation of the aetiology of the remaining unexplained portion of familial colorectal cancer (CRC) [1, 2]. Analogous to the multiple adenoma syndromes familial adenomatous polyposis and MUTYH-associated polyposis, individuals with hyperplastic polyposis syndrome (HPS) also develop CRC on a background of multiple polyps throughout the colon but in contrast, most of the polyps in HPS demonstrate serrated morphology. HPS was first described in 1977 by Spjut and Estrada [3], frequently presents with features consistent with a genetic predisposition to CRC [4], and is currently defined by the World Health Organization (WHO) criteria as at least five histologically diagnosed hyperplastic polyps proximal to the sigmoid colon, two of which are greater than 10 mm in diameter OR any number of hyperplastic polyps occurring proximal to the sigmoid colon in an individual who has a first-degree relative with hyperplastic polyposis OR more than 30 hyperplastic polyps of any size but distributed throughout the colon [5]. The WHO criteria were originally introduced to distinguish HPS from the common observation of satellite hyperplastic polyps around rectal cancers and diminutive distal colon lesions, and to highlight observations that even small numbers of larger hyperplastic polyps in the proximal colon may be associated with increased malignant potential [6]. However, because such definitions are necessarily stringent and somewhat arbitrary, many individuals and families with multiple hyperplastic polyps will fall short of these criteria [7]. Since the publication of the criteria in 2000, several investigators have proposed modifications to address these limitations. Higuchi and Jass have suggested that atypical serrated polyps (these include sessile serrated adenomas, serrated adenomas and mixed polyps) be included in the total polyp count which can be cumulative over time [8]. Variations on the threshold polyp count have been proposed, with Chow et al. [9], Rashid et al. [10], Hyman et al. [11], and Boparai et al. [12], all favouring a count of 20 hyperplastic polyps, and Carvajal-Carmona [13] using ten, instead of a count of 30 as described by the criteria. As reflected in the WHO criteria, HPS presents with extensive phenotypic heterogeneity not only with respect to the number and size of polyps, but also with regard to presence of CRC, polyp histology, sex ratios, age of onset, and the presence of a family history of CRC [10, 14–22] (Table 1). The underlying basis for the observed phenotypic heterogeneity is currently unclear; however, an analysis of phenotype in a large series of high-risk patients with multiple serrated polyps may contribute to our understanding of this heterogeneity by identifying patterns of inheritance and relationships between clinical features. In this, the largest such patient group studied to date, we examined the spectrum of presentations as an initial step to establishing a modern classification for this condition upon which to base gene discovery programmes, a procedure best carried out in a high-risk population.
Table 1

Published series of HPS cases where n was greater than five individuals, highlighting the phenotypic diversity of HPS

AuthorYearCases HPS (n)Mean age at diagnosis (years)Males (%)Number of polyps observedCRC (%)CRC in proximal colon (%)Family history of CRC (%)
Buchanana 200912649505-150405959
Boparai [12]20097756NS2-5335NSNS
Chow [9]2006384455Multiple264050
Carvajal-Carmona [13]2007324666multiple25NS59
Renaut [19]2001285854Multiple29NS39
Yeoman [40]2007246142Multiple548417
Ferrandez [15]2004155366Multiple0NS0
Lage [16]20041458NS19-100436733
Hyman [11]2004136238Multiple547138
Rashid [10]2000135854Multiple77NS38
Leggett [17]200112574230 to >10058NS17
Rubio [20]20061061806-159704310
Spjut [3]1977953NSMultiple11NSNS
Williams [21]19807378650-1500NS14
Torlakovic [30]19966578350-10067NSNS
Place [18]199966010050-1005010014

NS not specified; multiple upper limit of polyp numbers not specified

aCurrent manuscript data

Published series of HPS cases where n was greater than five individuals, highlighting the phenotypic diversity of HPS NS not specified; multiple upper limit of polyp numbers not specified aCurrent manuscript data

Patients and methods

The use of the term serrated polyp in this report encompasses any polyp with serrated architecture [23], and includes both common (hyperplastic or metaplastic) and advanced (serrated adenoma, sessile serrated adenoma, and mixed polyp) lesions. Due to the limitations of the WHO criteria, this cross-sectional study comprised 126 patients with multiple serrated polyps (five or more) recruited from genetics clinics in Australasia (n = 94) and North America (n = 32) regardless of family history of polyps and cancer. Using this approach which targets high-risk patients, we are unlikely to have recruited elderly patients with common distal serrated polyps, whilst at the same time recruiting patients with clinically significant disease who may have fallen short of the current WHO criteria. Thirty-eight patients from Australasia and ten from North America have been reported previously [9, 24]. Clinical and pathology data were extracted from histology reports, minimum polyp counts were derived from serial colonoscopy reports, where available, accounting for polyps removed at each procedure. Patients with polyps demonstrating hamartomatous features were not included in the study. Smoking status was recorded as never/ever and note was made of whether the participants were currently smoking. Patients gave written informed consent to participate in the research. The study was approved by the Human Research Ethics Committee (HREC) of Queensland Institute of Medical Research under the Genetics of Serrated Neoplasia project (QIMR HREC Protocol P912). Self-reported paternal and maternal ethnicity was recorded where available. Colorectal cancers were verified in first-degree relatives (parents, children, and siblings of the proband) using histology reports. Where more than one instance of multiple serrated polyps was present in a family, family history used the youngest proband as a point of reference (n = 6). In 118 families, we were able to classify patients as either index cases (the initial presenting family member n = 89) or screening cases (where multiple serrated polyps were identified as a result of screening due to family history of colonic neoplasia, n = 32). All but two index cases presented due to abdominal symptoms (bleeding, pain, or change in habit). The remaining two cases were diagnosed as an incidental finding during investigations for a hernia repair and an incidental finding at population screening due to age, respectively. Polyp counts in the entire study group, as well as in index cases showed a bimodal distribution and fell into two groups (Fig. 1) about a cut-point polyp count of 80, and were classified as either moderate polyposis (<80 polyps) or dense polyposis (≥80 polyps). All screening cases were observed to be in the moderate polyposis group.
Fig. 1

Frequency of polyp count numbers showing the distribution of polyp counts in a bimodal pattern about a polyp count of 80 and a concentration of screening cases below this number

Frequency of polyp count numbers showing the distribution of polyp counts in a bimodal pattern about a polyp count of 80 and a concentration of screening cases below this number

Statistical analysis

The associations between categorical predictor variables were assessed for statistical significance using an exact chi-squared test and odds ratios where appropriate. Comparison of means for age and minimum polyp count data were made using t tests. Missing data were excluded from the analysis. Multivariate analysis was used for estimating the odds ratios and 95% confidence intervals for the association between variables and two categorical outcomes of polyp number (moderate versus dense polyp count). All P values were two-sided and a P value <0.05 was considered as statistically significant. SPSS version 17 was used for all statistical analysis. In order to limit the effects of ascertainment bias, any significant findings were re-analysed in the subset of index cases.

Results

Characteristics of multiple serrated polyp patients

Table 2 shows that approximately one-half of patients were female (one patient unreported gender), and almost all were of Northern European ancestry, predominantly English, Irish, Scots, Welsh, French or French-Canadian, German, Swedish and Dutch. Six patients (5%) reported Italian, Greek or Middle-eastern ancestry (two of each). Two patients reported Anglo-Maori and Anglo-Middle-eastern ethnicity, respectively, and a third patient had a Jamaican parent. Two patients from a single family reported European-Russian-Jewish ancestry.
Table 2

Baseline characteristics of the participants in the study

CharacteristicNumber/mean (SD)TotalPercentage/range
White Ethnicity (Northern European)11412095.0%
Sex female6212549.6%
Age at presentation (years)49.0 (13.60)12418-86
 <50 years6112449%
 ≥50 years6312451%
Currently smoking218724%
Ever smoking518858%
Colorectal cancer4911941%
Proximal CRC244159%
Mean reported polyp number39 (31.61)1165-150
Adenomas9811585%
Advanced serrated polyps477067%
Family history of 1st degree relative with CRC6310759%
Family history of first or second degree relative with CRC669173%
Baseline characteristics of the participants in the study Patients from North America did not differ significantly from patients from Australia with respect to rates of CRC. CRC was diagnosed in 41% of patients, the majority of which were proximal (CRC site could not be confirmed in eight patients). Nine of the 24 patients (38%) with a proximal CRC had multiple (two to four) CRCs in the proximal colon and all but one of these were synchronous (Table 3). Multiple proximal CRCs were divided equally between males and females. No multiple CRCs were seen within in the distal colon; however, a further two patients had both a proximal and a distal CRC. Overall, 11 of 40 patients had multiple CRC (28%). Females with CRC were more likely to present with proximal malignancy than with distal CRC, whilst males with CRC were evenly divided between sites.
Table 3

Univariate analyses of phenotypic features and risk factors in 126 patients

ExposureNumber/mean (SD)TotalPercentage/rangeSignificance (P value)
Age at presentation (years)
 Females49 (45.16)6219-860.98
 Males49 (45.76)6118-67
 With CRC51(46.50)4918-860.91
 Without CRC48 (44.89)6819-67
Colorectal cancer
 Females235939%0.58
 Males265944%
CRC proximal244159%
 Multiple proximal CRC92438%0.04
 Multiple distal CRC0180%
 Female CRC—proximal131872%0.12
 Male CRC—proximal112348%
CRC Distal
 <50 years of age122060%0.02
≥50 years of age41922%
Mean reported polyp number39 (31.61)1165-150
 With CRC47 (36.09)435-1500.13
 Without CRC35 (28.50)685-150
 Females34 (27.76)565-1500.44
 Males44 (34.66)595-150
 Age group <50 years45 (36.53)555-1500.03
 ≥50 years34 (25.84)595-129
 With first degree relative with CRC32 (25.65)605-1500.008
 Without first degree relative with CRC53 (41.29)4211-150
 With any degree relative with CRC36 (29.78)645-1500.003
 Without any degree relative with CRC58 (36.58)2511-129
Smoking
 Current51 (37.95)215-1290.43
 Not currently smoking34 (28.41)665-150
 Ever41 (31.53)525-1290.56
 Never32 (30.52)375-150
Adenomas
 CRC424398%0.03
 Without CRC546781%
Advanced serrated polyps
 CRC192868%0.92
 Without CRC263967%
 Females283874%0.44
 Males213364%
 <50 years of age193151%0.31
≥50 years of age273773%
Univariate analyses of phenotypic features and risk factors in 126 patients There was no significant difference in mean age at presentation between the sexes (P = 0.98), or between patients with and without CRC (P = 0.91), however, patients presenting with CRC before age 50 were significantly more likely to have a distal cancer than were patients who presented with a CRC at 50 years or older (60% vs. 22%; P = 0.022), and patients presenting before age 50 had significantly more polyps (45 vs. 34; P = 0.03). Approximately three-quarters of patients had a first- or second-degree relative with CRC. Fifty-nine percent of the patients had a first-degree relative with CRC (60% of females and 59% of males; P = 0.90). Fifty-eight percent of participants had smoked for more than 3 months, and 24% of the participants were currently smoking. There was no difference between the sexes for current smoking status, with 22% of males and 30% of females continuing to smoke. Many patients (85%) had at least one polyp clearly reported as an adenoma, and CRC was significantly associated with the presence of these lesions (P = 0.03). Specialist pathology review was carried out by two gastrointestinal pathologists (JRJ and NIW) and serrated polyp sub-classification (common vs. advanced serrated polyps) was available on 70 patients. Approximately two-thirds had at least one advanced serrated polyp, and this proportion did not differ between patients with and without CRC. Though advanced serrated polyps were more likely to arise in females and those presenting at 50 years or older, the differences did not attain statistical significance.

Number of serrated polyps

The mean reported number of hyperplastic polyps per patient was 39 (Table 2). We found no difference in mean reported polyp number by sex, CRC, between patients with and without advanced serrated polyps, (Table 3) or between patients from Australia and North America. Mean reported polyp count was 40% lower in patients with a first-degree relative with CRC (32, 95% CI 26-39) compared to patients without a first-degree relative with CRC (53, 95% CI 41-64; P = 0.008). Moreover, there was also a significant difference in the mean reported polyp count between the patients with any first- or second-degree relative with CRC (36, 95% CI 29-44) and without any relative with CRC (58, 95% CI 43-73; P = 0.003). Current smokers had a higher reported polyp count (51 vs. 34; P = 0.043).

Ascertainment issues

Where information could be obtained, index cases comprised 89/122 multiple serrated polyp patients (73%) and the characteristics of these patients and those identified due to screening (n = 32, 27%) are shown in Table 4. When gender and family history of CRC were analysed in the first presenting patient in a family, mean reported polyp count was significantly lower in females (39 vs. 48; P = 0.047) and in patients with a first-degree relative with CRC (34 vs. 55; P = 0.026) though in both cases, the variance was large. Consistent with these findings, the mean reported polyp count in individuals screened because of family history was low, as was the rate of CRC in these asymptomatic patients. In three screening cases, patients were examined due to non-malignant colonic neoplasia in a relative, and all of these had relatively high polyp counts.
Table 4

Comparison of case characteristics according to ascertainment (index vs. screening cases)

VariableNumber (%) Index caseP valueNumber (%) Screening caseP value
GenderMale49 (55)13 (41)
Female40 (45)NA19 (59)0.22
CRCYes37 (43)09 (31)
No48 (57)NA20 (69)0.28
FDR with CRCYes36 (48)24 (88)
No39 (52)NA03 (12)a 0.0002b
VariableMean (SD)Mean (SD)
Age48 (14)NA50 (12)0.49
Mean polyp count44 (34)NA27 (21)0.048
Mean polyp countMale48 (36)0.04727 (20)0.82
Mean polyp countFemale39 (30)26 (22)
Mean polyp countFDR with CRC34 (28)0.02626 (19)0.49
Mean polyp countNo FDR with CRC55 (37)43 (29)

aCases screened due to family history of colonic neoplasia (non-malignant, n = 3)

bP value from two-sided Fisher’s exact test

Comparison of case characteristics according to ascertainment (index vs. screening cases) aCases screened due to family history of colonic neoplasia (non-malignant, n = 3) bP value from two-sided Fisher’s exact test In 47 families, Lynch syndrome could be excluded by immunohistochemistry for mismatch repair genes coupled with BRAF mutation testing. In two families, both Lynch syndrome and multiple serrated neoplasms segregated independently, and therefore family history of cancer information from these two families was not considered in this study. These two families have been described in detail as case reports elsewhere [25].

Polyp number category

Seventy-three percent (n = 66) had a reported number of between five and 79 serrated polyps (moderate polyposis), and the remainder had 80 or more (dense polyposis; Table 5). Females were significantly under-represented in the dense polyposis group (P = 0.02). Family history of CRC was inversely associated with polyp count category with the dense polyposis group having significantly less family history than those with moderate polyposis (P = 0.049). Though the rate of CRC did not differ between the two groups, patients presenting with CRC in the dense polyposis group were more likely to have a distal CRC. In contrast, proximal CRC predominated in the moderate polyposis group. Patients who met WHO criterion 3 for HPS (>30 hyperplastic polyps) were also significantly less likely to have a family history of CRC (P = 0.04), though no male predominance was seen, nor were distal CRC more common. Current smokers were more prevalent in the higher polyp count categories for both classifications but this was not statistically significant (P = 0.39 and 0.44). Multivariate analysis indicated that both the male predominance and the lack of family history of CRC were independent predictors of dense polyposis (Table 6).
Table 5

Univariate analysis of risk variables for a moderate or dense serrated polyp count in the index cases

Moderate (5-79 polyps)Dense (80 polyps or more)
n = 66n = 14
Mean (SD)Mean (SD)P value
Age (years)48.2 (13.6)44.5 (15.1)0.36a
N (%)N (%)OR (95% CI), P value
Gender
 Female34 (50%)2 (14%)6.0 (1.25-28.86),
 Male34 (50%)12 (86%)0.018b
CRC
 No41 (64%)6 (43%)2.38 (0.73-7.7)
 Yes23 (36%)8 (57%)0.23b
CRC Site
 Proximal13 (62%)1 (17%)8.13 (0.79-82.73)
 Distal8 (38%)5 (83%)0.077b
First degree relative with CRC
 No27 (47%)10 (77%)0.26 (0.07-1.05)
 Yes31 (53%)3 (23%)0.066b
First or second degree relative with CRC
 No16 (29%)8 (62%)0.25 (0.07-0.88)
 Yes40 (71%)5 (38%)0.049b

aIndependent samples t test for comparison of age at presentation between moderate and dense polyp groups

bP value from two-sided Fisher’s exact test

Table 6

Logistic regression analysis of putative predictors of a dense serrated polyp count in the index cases only

Dense polyp group (80-150 polyps)OR95% Confidence intervalP value
LowerUpper
Male gender9.51.5857.120.014
First degree relative with CRC0.170.0330.870.034
Occurrence of CRC1.940.448.560.38

The moderate polyp group (5-79 polyps) was the reference group with age, ethnicity, and recruitment site included as co-variates in the final analysis of main effects

Univariate analysis of risk variables for a moderate or dense serrated polyp count in the index cases aIndependent samples t test for comparison of age at presentation between moderate and dense polyp groups bP value from two-sided Fisher’s exact test Logistic regression analysis of putative predictors of a dense serrated polyp count in the index cases only The moderate polyp group (5-79 polyps) was the reference group with age, ethnicity, and recruitment site included as co-variates in the final analysis of main effects

Discussion

In this study, we examined the spectrum of phenotypic features in a large group of patients with multiple serrated polyps recruited from genetics clinics. Our results demonstrate significant phenotypic heterogeneity and suggest that both personal and familial risks of CRC in these patients are associated with multiple factors. Multiple serrated polyp patients demonstrated a high level of CRC risk, with 41% of participants presenting with CRC, a figure consistent with the findings of multiple reports [9–11, 16, 17, 19, 20, 22]. In contrast, two reports have suggested that HPS is not associated with an increased risk of CRC [15, 21]. This may reflect variation in the prevalences and exposures of genetic and environmental risk factors, respectively, within these local populations. Though polyp numbers were higher in patients with CRC [12], neither polyp numbers, nor the presence of advanced serrated polyps significantly determined whether a patient presented with CRC. Consistent with a previous report however, CRC was significantly associated with the presence of adenomas [20]. Dysplasia in co-existing polyps has also been reported previously as a risk factor for CRC [17]. Adenomas are common in the general population and it is likely that the factors which contribute to the growth and development of serrated polyps in these patients also act to increase the growth of a limited number of micro-adenomas [26]. CRC arose in the proximal colon more often than would be expected [27], with proximal cancers arising more frequently in females. A high rate of multiple synchronous CRCs was observed, with multiplicity significantly more common in the proximal colon when compared to the distal colon. In CRC arising via the serrated pathway, multiplicity and proximal location have been previously reported as associations [27, 28]. However, in patients less than 50 years, CRCs were more likely to be distal, which has been reported recently as a feature of young-onset CRC in general [29]. One of the largest HPS series reported to date (38 patients with a mean age at presentation of 44 years) found that 60% of CRC arose in distal sites [9]. This is an important finding as the emphasis placed on the proximal colon by the current WHO criteria may serve to distract from the risk of CRC in the young onset patient with multiple distal lesions whose presentation falls short of the current criteria. A slight male preponderance of 58% can be calculated overall from the published reports on HPS [9–11, 13, 14, 16–22, 30], and notably the St. Mark’s study of 1980 suggested that HPS was a disorder of young males [21]. No evidence of a male bias for multiple serrated polyps was observed in our 126 patients, displaying an approximately equal sex ratio when analysed overall. However, considerable differences were observed when this group of multiple serrated polyp patients was stratified. The group with the highest polyp numbers and the fewest relatives affected with CRC was predominantly male, and this is consistent with at least two previous reports, and may explain the results of the St. Mark’s series of 1980 [21]. The question arises as to whether these two results regarding gender and family history of CRC might reflect ascertainment bias. It could be postulated that individuals screened because of CRC in a relative may be more likely to have a lower polyp count because they are asymptomatic, and females may be more likely to present for screening. However, relationships between polyp count and both gender and family history of CRC demonstrated this same pattern when only index cases were examined. As would therefore be expected, asymptomatic cases screened because of family history of colonic neoplasia demonstrated lower polyp counts and a low rate of CRC. In this study, we found a significant increase in polyp numbers associated with direct current exposure to cigarette smoke, and suggests that rather than having a causal role in HPS, smoke exposure may be associated with modulation of phenotype, as manifested by increased polyp numbers. This enhancement of phenotype was not unexpected as population-based studies have consistently shown that the association between smoking and colorectal cancer was largely due to the strong effect of smoking on the subset of CRC which arose through the serrated neoplasia pathway [10, 31–33]. Smokers are more likely to present with hyperplastic polyps, even in asymptomatic individuals [34], with the most significant association between smokers and serrated neoplasia in the population having both hyperplastic and adenomatous polyps [35-37], a phenotype shared with individuals with HPS. As has been demonstrated in this report, multiple serrated polyps and CRC in a background of multiple serrated polyps, both can occur in the absence of smoking further supporting the premise that smoking is likely to be a modifier of phenotype rather than a causal factor. The two most significant predictors of increased polyp number were male sex and lack of family history of CRC, and this was independent of smoking status. A family history of CRC in first-degree relatives has been reported in HPS by several authors [9–11, 19]. In our study, patient recruitment was effected through high-risk clinics, rather than through population-based screening, and even though our findings for the rate of first-degree relatives with CRC however are completely consistent with an independent large series from the UK describing 32 HPS patients [13], this method of recruitment is likely to have inflated the risk of having affected relatives. Importantly, 40% of the patients in this study did not have a first-degree relative with CRC, suggesting that patients with multiple serrated polyps from genetics clinics are equally likely to be referred in the absence of a first-degree family history of CRC. Our current study demonstrated that family history of CRC was relatively low in the group of patients with very high polyp counts, thus highlighting the possibility of genetic heterogeneity as a basis for the phenotypic variation observed in this condition. Though this finding emerged from a stratified analysis, separation of the predispositions was incomplete; suggesting that predisposition to serrated neoplasia may be a complex genetic condition. In summary, our data support the notion, previously proposed by multiple authors [6, 10, 30, 38, 39], that patients with multiple serrated polyps have a heterogeneous condition. The clinical importance in identifying HPS is highlighted by the observation that 40% of HPS patients in our cohort presented with CRC, frequently in the proximal colon with an increased risk of multiplicity. Also of clinical importance is the risk of CRC in relatives which is likely to exceed that of the population, though quantitation of this risk remains problematical [6, 39]. The study demonstrated that young-onset patients with multiple serrated polyps are more likely to develop a distal CRC despite the emphasis placed on proximal disease by the WHO criteria. Importantly, the study has presented evidence for consideration potentially highlighting heterogeneity in the mode of inheritance of serrated polyp predisposition, with the identification of a younger-onset group with highest polyp counts, male gender and little family history of CRC, features alluded to in an influential publication in 1980 [21]. The novel finding that family history varies inversely with polyp count and gender, is unlikely to be confounded by age, and is independent of ascertainment and smoking, and suggests that patients with multiple serrated polyps have a complex condition modified by a multitude of genetic, environmental, and sex-specific factors. The development of new clinical criteria with a biological basis [13] to better define this predisposition and to identify those with the highest personal and familial risks of CRC are warranted.
  38 in total

1.  Phenotypic and molecular characteristics of hyperplastic polyposis.

Authors:  A Rashid; P S Houlihan; S Booker; G M Petersen; F M Giardiello; S R Hamilton
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

2.  A first-degree relative with colorectal cancer: what are we missing?

Authors:  Ellen Kampman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-01       Impact factor: 4.254

3.  Hyperplastic polyposis and the risk of colorectal cancer.

Authors:  Neil H Hyman; P Anderson; H Blasyk
Journal:  Dis Colon Rectum       Date:  2004-12       Impact factor: 4.585

4.  Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.

Authors:  Wade S Samowitz; Hans Albertsen; Carol Sweeney; Jennifer Herrick; Bette J Caan; Kristin E Anderson; Roger K Wolff; Martha L Slattery
Journal:  J Natl Cancer Inst       Date:  2006-12-06       Impact factor: 13.506

5.  The significance of epithelial polyps of the large bowel.

Authors:  H Spjut; R G Estrada
Journal:  Pathol Annu       Date:  1977

Review 6.  Hyperplastic-adenomatous polyposis syndrome.

Authors:  R J Place; C L Simmang
Journal:  J Am Coll Surg       Date:  1999-05       Impact factor: 6.113

7.  Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study.

Authors:  Karam S Boparai; Elisabeth M H Mathus-Vliegen; Jan J Koornstra; Fokko M Nagengast; Monique van Leerdam; Carel J M van Noesel; Martin Houben; Annemieke Cats; Liselotte P van Hest; Paul Fockens; Evelien Dekker
Journal:  Gut       Date:  2009-08-25       Impact factor: 23.059

Review 8.  My approach to serrated polyps of the colorectum.

Authors:  T Higuchi; J R Jass
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

9.  Morphology of sporadic colorectal cancer with DNA replication errors.

Authors:  J R Jass; K A Do; L A Simms; H Iino; C Wynter; S P Pillay; J Searle; G Radford-Smith; J Young; B Leggett
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

10.  Hyperplastic polyposis in the New Zealand population: a condition associated with increased colorectal cancer risk and European ancestry.

Authors:  Andrew Yeoman; Joanne Young; Julie Arnold; Jeremy Jass; Susan Parry
Journal:  N Z Med J       Date:  2007-11-30
View more
  26 in total

1.  Risk factors: Hyperplastic polyposis syndrome and risk of colorectal cancer.

Authors:  Joanne P Young; Susan Parry
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11       Impact factor: 46.802

Review 2.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

Review 3.  Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management.

Authors:  Priyanka Kanth; Jade Grimmett; Marjan Champine; Randall Burt; N Jewel Samadder
Journal:  Am J Gastroenterol       Date:  2017-08-08       Impact factor: 10.864

4.  A serrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome.

Authors:  Karam S Boparai; Evelien Dekker; Mirjam M Polak; Alex R Musler; Susanne van Eeden; Carel J M van Noesel
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 5.  Genetic predisposition to colorectal cancer: where we stand and future perspectives.

Authors:  Laura Valle
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Type 1 serrated polyposis represents a predominantly female disease with a high prevalence of dysplastic serrated adenomas, without germline mutation in MUTYH, APC, and PTEN genes.

Authors:  Marco Petronio; Stephane Pinson; Thomas Walter; Marie-Odile Joly; Valerie Hervieu; Julien Forestier; Jean-Christophe Saurin
Journal:  United European Gastroenterol J       Date:  2015-07-24       Impact factor: 4.623

Review 7.  Management of Serrated Polyps of the Colon.

Authors:  Claire Fan; Adam Younis; Christine E Bookhout; Seth D Crockett
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03

8.  Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics.

Authors:  Daniel D Buchanan; Kevin Sweet; Musa Drini; Mark A Jenkins; Aung Ko Win; Dallas R English; Michael D Walsh; Mark Clendenning; Diane M McKeone; Rhiannon J Walters; Aedan Roberts; Sally-Ann Pearson; Erika Pavluk; John L Hopper; Michael R Gattas; Jack Goldblatt; Jill George; Graeme K Suthers; Kerry D Phillips; Sonja Woodall; Julie Arnold; Kathy Tucker; Amanda Muir; Michael Field; Sian Greening; Steven Gallinger; Renee Perrier; John A Baron; John D Potter; Robert Haile; Wendy Frankel; Albert de la Chapelle; Finlay Macrae; Christophe Rosty; Neal I Walker; Susan Parry; Joanne P Young
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

9.  Extracolonic cancer risk in patients with serrated polyposis syndrome and their first-degree relatives.

Authors:  Yark Hazewinkel; Johannes B Reitsma; Fokko M Nagengast; Hans F Vasen; Theo A M van Os; Monique E van Leerdam; Jan-Jacob Koornstra; Evelien Dekker
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

10.  Multiplicity and molecular heterogeneity of colorectal carcinomas in individuals with serrated polyposis.

Authors:  Christophe Rosty; Michael D Walsh; Rhiannon J Walters; Mark Clendenning; Sally-Ann Pearson; Mark A Jenkins; Aung Ko Win; John L Hopper; Kevin Sweet; Wendy L Frankel; Melyssa Aronson; Steve Gallinger; Jack Goldblatt; Kathy Tucker; Sian Greening; Michael R Gattas; Sonja Woodall; Julie Arnold; Neal I Walker; Susan Parry; Joanne P Young; Daniel D Buchanan
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.